People

The People

Governance grade: C+. RadNet is a 40-year founder-run company with a capable, long-tenured operating bench but a concentration of power in its 81-year-old CEO — who also chairs the board, personally owns 99% of the physician group that bills through nearly all California and Arizona centers, and whose family trust leases the company a New York apartment. Independent directors qualify on paper, but the board skews old (six of six nominees aged 64–83) and meets infrequently. Skin in the game is lower than the company's marketing suggests: all directors and officers hold just 5.14% directly. Pay is reasonable, operators are deep, and there are no open regulatory actions against the team — but alignment comes from tenure and employment inertia more than equity.

1. The People Running This Company

The operating spine is unusually stable: Berger 40 years, Hames 30 years, Forthuber 20 years, Stolper 22 years, Patel 16 years. Patel's promotion to COO and Wesdorp's elevation to run Digital Health (renamed from Chief Science Officer role for Sorensen) signal a gradual generational handoff — but Berger remains chairman, CEO, and president at 81, with no disclosed retirement date. The company has an "emergency succession plan" but has not publicly named a successor.

2. What They Get Paid

Berger's 2025 package jumped 33% year-over-year to $12.1M, driven by a one-time $9M equity grant (300% of base, up from 67% of base in 2024). He took zero cash bonus — unusual for a CEO pay package, and a partially sympathetic choice: Berger is a net equity receiver, but the grant vests over four years regardless of performance, so the "at risk" framing is weak. For context, RadNet's revenue is $2.04B — putting Berger at roughly 0.59% of revenue in total comp, a ratio that is elevated versus healthcare-services peers of similar scale but not outrageous.

Pay design has reasonable mechanics:

• Pearl Meyer is the independent comp consultant (retained since 2016; no other work for the company).
• Peer group is 16 healthcare facility/services companies in the $1–5B revenue range (Acadia, Encompass, Select Medical, Option Care, etc.).
• Clawback policy adopted November 2023; no excise tax gross-ups; no option repricing without shareholder approval; hedging banned.
• Say-on-pay support: 89% (2024) → 83% (2025). The declining number is a yellow flag — not a revolt, but meaningful stockholder discomfort is building, plausibly around Berger's step-up.

3. Are They Aligned?

Ownership: the "management owns 25%" claim vs. reality

The company markets itself as having "management owns over 25% of common stock." That is misleading in the strictest sense: the proxy shows all directors and executive officers combined own 5.14% of the company. The 25% claim only makes sense if you include the HFB Heirs' Trust II (5.80%) — Berger's children's trust, which Berger disclaims beneficial ownership of and does not control — plus institutional holdings tied to long-time shareholders. Berger himself owns 0.66% direct (518,405 shares including 20,000 held by his spouse and 26,000 in-the-money options).

For a 40-year founder-CEO drawing ~$12M/year, that is thin direct skin in the game. By comparison, Sorensen (Chief Strategy Officer, joined 2023) owns 1.53% — more than twice Berger's direct stake — because his DeepHealth stock consideration was larger.

Insider buying vs. selling

Over the past six months, insiders have made 11 open-market sales and zero open-market purchases, for roughly $9.3M of net selling. Sorensen additionally donated 7,000 shares to charity. None of this is large relative to outstanding, but the uniformity is notable — every sale, no purchase, through a period when the stock traded in the $60–82 range. Some of this reflects mechanical tax-cover on vesting; however, Patel and Forthuber's volumes are larger than straightforward withholding.

Dilution: who pays for the equity grants

The 2025 $16.6M aggregate NEO equity grant is 3× the 2024 equivalent, driven largely by Berger's one-time $9M award. The 2026 aggregate of $15.1M is only slightly smaller. On a 75M-share base, that's ~30 bps of annual dilution just from the top five — tolerable, but not trivial on a company that also grants to 11,000 employees and runs ~2.2M shares of outstanding unvested awards plus available plan shares of 2.2M.

Related-party transactions: the single most important governance issue

Skin-in-the-game score: 6 / 10

Why 6 and not higher: Berger personally owns only 0.66% of shares outstanding despite 40 years of tenure and a large compensation history; the HFB Heirs Trust II is his children's not his; insider activity is one-way (selling) over the last six months; and a top officer has material pledged shares. Why 6 and not lower: the operating bench is unusually loyal (Hames, Forthuber, Stolper all 20+ years); Sorensen holds 1.53% directly; 2026 pay shifts heavily into equity; clawback, hedging ban, and no gross-ups are in place; and institutional holders (BlackRock, RTW) provide outside pressure. Upgrade would require Berger visibly adding to his position in the open market or a credible, named succession plan.

4. Board Quality

Expertise heatmap (self-reported in Director Skills matrix)

Independent director pay (FY2025)

What the board matrix actually shows

Real independents: four of six nominees. Swartz, Levitt, Jacobs, Spurlock. All qualify under NASDAQ rules and two (Swartz, Levitt) are audit-committee financial experts. Comp committee chair Levitt is a CPA, a very reasonable choice.

Concentrated power: Berger is Chairman, CEO, and President. The only check is Swartz as Lead Independent Director. Swartz has been on the board since 2004 — a 22-year tenure that is itself an independence question under ISS/Glass Lewis heuristics (most advisors flag independence erosion past 10–15 years). Levitt is at 21 years. Two of four "independent" directors have been sitting longer than many employees.

Age and concentration: The full board slate is 64, 64, 69, 81, 82, 83. Five of six are 64 or older. There is no director under 60 and no refreshment policy disclosed. The company has diversity language in its nominating charter but no age/tenure limits.

Meeting cadence is light: Audit committee met 4 times in 2025 (minimum acceptable), Comp 5 times, Nominating & Governance once. A committee that reviews CEO succession, related-party transactions, and governance practices meeting only once per year is a gap — especially given the BRMG renewal and the HFB Heirs Trust II lease that live in its remit.

Section 16(a) delinquencies: The 2025 proxy confirms late Form 4 filings for Katz (1), Forthuber (2), Patel (2), and Hames (2). The company characterizes all as stemming from restricted-stock vestings, which is a benign explanation, but four separate officers making late filings in one year reflects a compliance weakness.

AGM attendance: "None of our directors or stockholders attended the 2025 Annual Meeting of Stockholders." This is a literal reading of a formality, but it also captures the tone: the board prefers paper governance to visible accountability.

5. The Verdict

Grade: C+.

Strongest positives. A genuinely capable operating team with 20+ year tenures across ops, finance, and regional leadership. Two high-quality external hires (Wesdorp ex–Hellman & Friedman/Philips, Sorensen ex–Siemens Healthcare NA) now running the Digital Health strategy that drives the bull case. Pay is benchmarked by a real consultant (Pearl Meyer), with clawback, hedging ban, no gross-ups, and majority director voting. Disclosure is clear and readable — a non-trivial green flag for a founder-led company. No active SEC or DOJ investigations into the team; the only outstanding litigation of note is a consumer data-breach class action (Pfeiffer v. RadNet) that has been settled.

Real concerns. (1) Key-person risk at Berger: 81 years old, three titles, no named successor. (2) BRMG — CEO personally owns 99% of the professional group that supplies physicians for nearly all California and Arizona centers, with a 10-year auto-renewed management agreement that pays RadNet 78% of BRMG's collections. Untangling this in any transition event would be hard. (3) HFB Heirs' Trust II: small-dollar but textbook related-party (NYC apartment rental to the CEO's family trust). (4) CEO direct ownership is 0.66% — thin for a 40-year founder with a $12M pay package. (5) Board is aging (64–83) and two "independent" directors have 21- and 22-year tenures. (6) Insider activity is 11 sales, 0 buys over six months. (7) COO has 177,649 pledged shares. (8) Say-on-pay support is eroding (89% → 83%).

What would move the grade up. Berger personally buying shares in the open market. A named, disclosed successor. A board-refreshment policy adding at least one director under 55 with healthcare-tech operating experience. A public plan for the BRMG unwind in a succession event. Removal of pledged-share permissions for executive officers.

What would move it down. Another BRMG amendment that increases CEO personal extraction, expansion of related-party arrangements, a margin-call forced sale by Patel, a sustained stock drop that coincides with continued one-way insider selling, or a CEO-continuity event without a pre-announced successor.

For an imaging roll-up of this scale and age, C+ is consistent with "the operators earn your confidence, the governance structure does not yet match the size of the business."